ANI Pharmaceuticals (ANIP) Q2 2026 earnings review
Top-Line Beats, But a Quiet Cut to the Flagship Story
ANI delivered a robust Q2 with total revenue up 26% YoY to $266M and Adjusted EBITDA jumping 32% to $71.6M. The Generics business is a reliable cash engine, and the new IP monetization deal with Harmony is already yielding high-margin profits. However, a major contradiction sits at the center of the report: Management heavily touted the 'outstanding' early metrics of their 90-person sales expansion for Cortrophin Gel in gout, yet quietly cut Cortrophin's full-year guidance by $27.5M at the midpoint. You do not lower the outlook for your flagship growth driver right after a massive commercial deployment unless base volumes are softening or the ramp is slower than modeled.
🐂 Bull Case
The Generics business grew 10% YoY, delivering steady cash flow. The Harmony Biosciences IP deal dropped $17.7M of nearly pure-margin revenue to the bottom line this quarter, proving the value of ANI's underlying assets.
The 90-person sales team targeting acute gouty arthritis is fully deployed. Management claims over 95% of reps generated multiple new patient cases, expanding the addressable market by an estimated 285,000 patients.
🐻 Bear Case
Despite management's bullish tone, FY26 Cortrophin guidance was cut from $540-$575M to $520-$540M. This implies a deceleration in the back half of the year just as the gout expansion should be accelerating.
ILUVIEN sales fell 16% YoY. While management cited international shipment timing, this segment has suffered from persistent Medicare market access issues, turning a former growth pillar into a severe laggard.
⚖️ Verdict: ⚪
Neutral. The company is executing well financially and generating cash, but the unexplained downward revision to the core Cortrophin growth story introduces significant execution risk for the back half of 2026.
Key Themes
The Flagship Guidance Disconnect
Cortrophin Gel grew 44% YoY to $117.1M, which looks great on paper. But management cut the FY26 revenue target by $27.5M at the midpoint. This directly contradicts the bullish narrative surrounding the new gout sales force. If the gout launch metrics are 'very positive' with balanced demand across podiatrists and primary care, the base business must be significantly underperforming to warrant a guidance cut.
IP Monetization Driving Immediate Returns
The Harmony Biosciences licensing deal for pitolisant is proving to be a masterstroke of capital allocation. In Q2 alone, it generated $17.7M in revenue ($9.7M in royalties, $8.0M in development milestones). With an additional $2.0M milestone expected in Q3 and ongoing royalties from WAKIX (a billion-dollar drug), this provides a massive, high-margin cash injection to fund the rare disease transformation without diluting shareholders.
ILUVIEN Reverses Course
ILUVIEN was the worst-performing segment, dropping 16.1% YoY to $18.7M. This segment grew significantly below the company average of +26%. Management blamed the timing of international shipments, but the structural reality is that Medicare Part D access issues (specifically co-pay foundation funding gaps) have plagued this asset for over a year. The turnaround plan is taking longer than expected.
Margin Compression is Structural
Non-GAAP Gross Margin compressed by 230 basis points YoY, falling from 64.9% to 62.6%. This is not a temporary blip. It is driven by the structural mix shift toward royalty-bearing products (like Cortrophin, which pays a high-20s percentage royalty to Merck) and a partnered generic product, compounded by the loss of the high-margin 180-day exclusivity on Prucalopride.
Generics Execution Providing Stability
The Generics segment continues to play its role perfectly, growing 9.7% YoY to $99.1M. The company has already launched 12 new products year-to-date and is on track to hit its target of at least 15 new launches in 2026. This operational excellence limits downside risk and fuels the high-growth Rare Disease investments.
Other KPIs
Accelerating. Up 32.4% YoY. This proves that despite the gross margin compression, management is successfully extracting operating leverage from the revenue base. A large contributor to this profitability jump is the high-margin revenue from the Harmony IP deal.
Reversing. Down 11.4% YoY. Management cited 'timing associated with ongoing and new projects.' A drop in R&D spend artificially inflates near-term operating income, so investors should expect this expense line to rebound in the back half of the year to support the 2027 pipeline.
Up significantly from $285.6M at the end of 2025. Unrestricted cash generated from operations was $115M in the first half of the year. The company's balance sheet is fortress-like, easily supporting the newly authorized $100M share repurchase program.
Guidance
Stable. The company reaffirmed total revenue guidance, implying 22% - 29% YoY growth. The shortfall from the Cortrophin cut is likely being offset by overperformance in Generics or higher-than-expected royalties from Harmony.
Decelerating. Lowered from the previous $540 - $575 million. This now implies 50% - 55% YoY growth, down from the originally modeled 55% - 65%. This is the most critical metric in the report and signals that base demand or the gout ramp is missing internal targets.
Stable. Guidance reaffirmed, implying 4% - 11% YoY growth. Given the 16% decline in Q2, hitting this target requires a significant second-half acceleration and flawless execution on international shipments.
Stable. Guidance reaffirmed, implying 24% - 31% YoY growth. This highlights the power of the Harmony milestone payments and generics cash flow to protect the bottom line even when the flagship drug misses top-line targets.
Key Questions
The Cortrophin Guidance Disconnect
If over 95% of reps in the new gout expansion are generating multiple new patient cases, why did you cut the full-year Cortrophin guidance by nearly $30M? Is base demand softening, or is the duration of therapy in gout shorter than expected?
ILUVIEN Structural Viability
ILUVIEN revenues fell 16% YoY. How much of this was truly just 'international shipment timing' versus the ongoing Medicare Part D foundation funding issues? Is this asset capable of returning to sustained double-digit growth?
Margin Floor Expectations
With non-GAAP gross margin compressing to 62.6% due to royalty mix and generic exclusivity cliffs, where do you see the long-term margin floor as Cortrophin continues to outgrow the rest of the business?